One of them, rapamycin, is under investigation for the prevention of graft-versus-host disease (GVHD). 2, 3 It has also been used to avert rejection in organ transplantation [4] [5] [6] and in the treatment of psoriasis 7 and rheumatoid arthritis. 8 Reported toxicities include neutropenia, thrombocytopenia and anaemia. 6, 7 Studies in cell lines have demonstrated considerable growth inhibition by rapamycin in the dose range 0-10 nm but with little increase in effect at higher concentrations (10-1000 nm). 9 This inhibition is believed to be the result of selective inhibition of S6 ribosomal protein kinase (p70
S6K
) activation thereby preventing cyclin-dependent kinase activation, retinoblastoma protein (pRB) phosphorylation and cell cycle progression. 10 When we included escalating concentrations of rapamycin in granulocyte-macrophage colony-forming cell (CFU-GM) assays we found a marked suppression of colony numbers ( Figure 1 ). The colony assays were set up by plating 1 × 10 5 mononuclear bone marrow in triplicate 1 ml aliquots of methylcellulose-containing serum (methocult H4230; Metachem Diagnostics, Nottingham, UK) and supplemented with recombinant human cytokines (100 ng/ml G-CSF (Granocyte; Chugai Pharma, London, UK, 1 ng/ml GM-CSF, 5 ng/ml IL-3 and 20 ng/ml SCF (First Link, West Midlands, UK)). The rapamycin was dissolved in ethanol which was present at a highest final concentration of 5 × 10 −3 % which alone had no effect on colony numbers. The rapamycin dose-response curve was biphasic with a sharp decline to 7% of control numbers at concentrations of rapamycin up to 10 nm and a more gradual decline at concentrations between 10 and 100 nm to ෂ3% of controls. Thus, rapamycin has considerable potential for inducing myelotoxicity. 
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